These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12598819)

  • 1. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluvoxamine as an adjunctive agent in schizophrenia.
    Silver H
    CNS Drug Rev; 2001; 7(3):283-304. PubMed ID: 11607044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
    Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
    Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
    Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 10. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study.
    Silver H; Barash I; Aharon N; Kaplan A; Poyurovsky M
    Int Clin Psychopharmacol; 2000 Sep; 15(5):257-61. PubMed ID: 10993127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial.
    Haji Seyed Javadi A; Shafikhani AA; Zamir SM; Khanshir ZF
    J Clin Psychopharmacol; 2018 Apr; 38(2):119-124. PubMed ID: 29432331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients.
    Silver H; Mandiuk N; Einoch R; Susser E; Danovich L; Bilker W; Youdim M; Weinreb O
    Int Clin Psychopharmacol; 2015 May; 30(3):158-66. PubMed ID: 25756551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy of chronic schizophrenic psychoses--neuroleptic plus serotonin reuptake inhibitor?].
    Salzmann E; Eikelmann B
    Psychiatr Prax; 1997 Sep; 24(5):253. PubMed ID: 9417552
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
    Zohar J; Keegstra H; Barrelet L
    Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.
    Chong SA; Tan CH; Lee HS
    J Clin Psychopharmacol; 1997 Feb; 17(1):68-9. PubMed ID: 9004072
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
    Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
    J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Expert Opin Pharmacother; 2004 Oct; 5(10):2053-8. PubMed ID: 15461540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.